Jump to content
RemedySpot.com

IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C

Rate this topic


Guest guest

Recommended Posts

Guest guest

J Infect Dis. 2011 Jul;204(1):84-93.

IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated

Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1

Hepatitis C.

ma K, CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y,

Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H.

Source

Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN.

Abstract

Background. Pegylated interferon, ribavirin, and telaprevir triple therapy is

a new strategy expected to eradicate the hepatitis C virus (HCV) even in

patients infected with difficult-to-treat genotype 1 strains, although adverse

effects, such as anemia and rash, are frequent. Methods. We assessed efficacy

and predictive factors for sustained virological response (SVR) for triple

therapy in 94 Japanese patients with HCV genotype 1. We included recently

identified predictive factors, such as IL28B and ITPA polymorphism, and

substitutions in the HCV core and NS5A proteins. Results. Patients treated

with triple therapy achieved comparatively high SVR rates (73%), especially

among treatment-naive patients (80%). Of note, however, patients who experienced

relapse during prior pegylated interferon plus ribavirin combination therapy

were highly likely to achieve SVR while receiving triple therapy (93%);

conversely, prior nonresponders were much less likely to respond to triple

therapy (32%). In addition to prior treatment response, IL28B SNP genotype and

rapid viral response were significant independent predictors for SVR. Patients

with the anemia-susceptible ITPA SNP rs1127354 genotype typically required

ribavirin dose reduction earlier than did patients with other genotypes.

Conclusions. Analysis of predictive factors identified IL28B SNP, rapid viral

response, and transient response to previous therapy as significant independent

predictors of SVR after triple therapy.

PMID: 21628662 [PubMed - in process]

Link to comment
Share on other sites

Guest guest

J Infect Dis. 2011 Jul;204(1):84-93.

IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated

Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1

Hepatitis C.

ma K, CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y,

Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H.

Source

Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN.

Abstract

Background. Pegylated interferon, ribavirin, and telaprevir triple therapy is

a new strategy expected to eradicate the hepatitis C virus (HCV) even in

patients infected with difficult-to-treat genotype 1 strains, although adverse

effects, such as anemia and rash, are frequent. Methods. We assessed efficacy

and predictive factors for sustained virological response (SVR) for triple

therapy in 94 Japanese patients with HCV genotype 1. We included recently

identified predictive factors, such as IL28B and ITPA polymorphism, and

substitutions in the HCV core and NS5A proteins. Results. Patients treated

with triple therapy achieved comparatively high SVR rates (73%), especially

among treatment-naive patients (80%). Of note, however, patients who experienced

relapse during prior pegylated interferon plus ribavirin combination therapy

were highly likely to achieve SVR while receiving triple therapy (93%);

conversely, prior nonresponders were much less likely to respond to triple

therapy (32%). In addition to prior treatment response, IL28B SNP genotype and

rapid viral response were significant independent predictors for SVR. Patients

with the anemia-susceptible ITPA SNP rs1127354 genotype typically required

ribavirin dose reduction earlier than did patients with other genotypes.

Conclusions. Analysis of predictive factors identified IL28B SNP, rapid viral

response, and transient response to previous therapy as significant independent

predictors of SVR after triple therapy.

PMID: 21628662 [PubMed - in process]

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...